



Raising Awareness. Saving Lives.

The FH Foundation®


Cat Davis Ahmed, VP Policy and Outreach

PA Policies: Can We Strike a Balance between
Appropriate Utilization and Appropriate Access?

FH: A Costly Burden



 **20%** of **Heart Attacks** Under Age 45
are due to




Hopkins P, Toth P. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17.




ALL PATIENTS PRESCRIBED A PCSK9



HIGH RISK PRESUMPTIVE FH PATIENTS



HIGH RISK ASCVD PATIENTS




Knowles, J., Howard, W., Karayan, L., Baum, S., Willemon, K., Ballantyne, C., & Myers, K. (2017). Access to Non-Statins Lipid Lowering Therapies in Patients at High-Risk of Atherosclerotic Cardiovascular Disease. Circulation, CIRCULATIONAHA.117.027705. <http://dx.doi.org/10.1161/circulationaha.117.027705>

* MI - Medium Intensity
** HI - High Intensity




Percentage of Patients in Plans Requiring Genetic Testing and Other Diagnostic Criteria for PCSK9 Inhibitors*




Doshi et al. Prior Authorization Requirements for PCSK9 Inhibitors across U.S. Private and Public Payers. *Circ Cardiovasc Qual Outcomes*. 2018 Jan;11(1):e003939. doi: 10.1161/CIRCOUTCOMES.117.003939.

*Some forms allowed providers to choose which type of diagnostic confirmation to provide. The percentages of patients in plans that only listed genetic testing for diagnostic confirmation of FH on their PA form for Praluent were 38% commercial, 63% HIX, 29% Medicare, and 20% Medicaid. For Repatha, these numbers were 40% commercial, 50% HIX, 4% Medicare, and 19% Medicaid.

Mean No. of PA Criteria or Fields on PA Form a Provider Must Complete to Receive Approval



Doshi et al. Prior Authorization Requirements for PCSK9 Inhibitors across U.S. Private and Public Payers. *Circ Cardiovasc Qual Outcomes*. 2018 Jan;11(1):e003939. doi: 10.1161/CIRCOUTCOMES.117.003939.



less than **10%** Diagnosed with FH
less than **1%** Prescribed PCSK9i
1,188 Prescribed

